Publication | Closed Access
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
171
Citations
0
References
2012
Year
Surgical OncologyCancer ManagementPathologyLux-lung 3OncologyAdvanced AdenocarcinomaCancer Cell BiologyClinical OncologyRadiation OncologyCancer ResearchMolecular OncologyFinal TextAsco Daily NewsCancer TreatmentCancer GeneticsMalignant DiseaseLung CancerTumoral PathologyMedicinePhase Iii Study
LBA7500 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.